Pharmfactor (belonging to the corporate group led by Biomedycyna Polska S.A.) has finalized the patent application submission process with the Patent Office of the Republic of Poland for inventions in the field of technologies used for manufacture of the active pharmaceutical ingredients (API) produced by the company.

The company’s activities in the scope of production of innovative biopharmaceuticals are supported by decades of experience, regularly complemented by novel solutions resulting from internal research and development projects as well as the cooperation with leading science centres.

Submission: Method of obtaining aprotinin and the product manufactured using this method

(pol. Sposób otrzymywania aprotyniny oraz produkt otrzymany tym sposobem)

Assigned number: P.434960

Submission: Method of obtaining hyaluronidase and the product manufactured using this method

(pol. Sposób otrzymywania hialuronidazy oraz produkt otrzymany tym sposobem)

Assigned number: P.435319

Pharmfactor’s business profile is in line with the current drug safety strategies of the member states of the European community. The coronavirus crisis revealed strong EU’s dependency on countries beyond our boundaries, especially China and India is case of APIs and medicines manufacturing.

APIs produced by Pharmfactor meet the pharmacopoeial criteria and registered quality specifications moreover they are characterized by high activity in comparison with market competitors which affects the economic efficiency of production and increased profit